2Morrow is a leader in digital behavioral health, providing evidence-based health and wellness programs to some of the nation's largest employers, states, and health plans. Founded in 2011 by a nurse and a medical device engineer, 2Morrow's vision is to increase access to care by combining behavioral science and smartphone technology. 2Morrow has helped over half a million people improve their lives using our digital health programs. At 2Morrow, evidence is part of our DNA. With over 20 studies and one of the few Phase III clinical trials in digital health, 2Morrow continues to be a the forefront of the emerging digital health and digital therapeutic industry.

4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our coveted genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology.

Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain. Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology.

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges. The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform. In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives.

Aksense is developing a quick blood test to help people who are suffering from healthcare-associated infections, with testing these infections in one minute with a portable electronic biosensor, without a lab or expert, saving lives, time, and money. Contact us to find out more.

Alva Health develops healthcare wearables for remote stroke monitoring. The company's wearables are patented and operate round-the-clock to identify stroke signatures and connect consumers with emergency services. Alva Health aims to transform stroke treatment and the ability to create, validate, and market revolutionary neurotechnologies.

Ankr recreates your brick-and-mortar clinic infrastructure including front desk, MA, scribe, and answering service in the cloud, so that your doctors can perform billable visits anywhere, anytime. Ankr is an Epic(R) and eClinicalWorks(R) Vendor Services partner and Athena(R) marketplace-certified vendor. Talk to us today to see why organizations across USA trust Ankr to increase revenue and quality of after-hours care!

Anumana is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments.

Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies for biomedical research, diagnostics, and therapeutic applications.

Astek is a precision diagnostics company, advancing the Jiddu system for confirming bacterial infections and assessing antibiotic sensitivity in various sample types: urine, CSF, effluent, and blood. This groundbreaking technology aims to enhance diagnostic speed and accuracy, reduce patient complications, and lower healthcare costs. Our initial focus is launching a urine-based test in 2025 that swiftly identifies UTI infections and determines antibiotic sensitivity within an hour.

Atom Bioworks is a developer of a pattern-recognition enabled DNA-antibody-mimic rational design platform for sensing and therapeutics of infectious diseases.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years.

Augmedics pioneers cutting-edge augmented reality technologies to improve surgical outcomes. The company’s revolutionary xvision Spine System® allows surgeons to see patients’ anatomy as if they have “x-ray vision” and accurately navigate instruments and implants during spine procedures. The first-of-its-kind, FDA-cleared xvision has been used to treat over 4,000 patients and implant more than 20,000 pedicle screws across 21 US states.

Aureka Biotechnologies is a biotech startup democratizing the pharmaceutical industry through our focused area of immunotherapeutic discovery. Empowered by our integrated digital biology and AI solutions, we enable partners to bring new medicines to patients efficiently. By integrating microfluidics, synthetic biology, and AI, we've developed a powerful drug discovery platform, accelerating the path from concept to market.

Autolomous is a company founded by Cell and Gene Therapy (CGT)- and software development experts, who have combined their skills to deliver elegant, seamless and agile solutions to the CGT sector. Autolomous will deliver the digital solutions necessary for CGT to achieve scalability, allowing more patients to benefit from these life changing therapies. The company is creating a portfolio of software solutions (AutoloMATE-solution platform), from electronic Batch Manufacturing Records (eBMR) to enabling the scheduling of the patient blood collections at hospital; the transport of those cells to the manufacturing facilities; enhancing traceability throughout the manufacturing process; supporting compliance with current and future regulatory requirements; expediting the drug product release; and the scheduled delivery of the patient-specific medicine to the hospital.

AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. We are redefining interventional therapy for severely calcified lesions with our Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.

Axio is a deep-science medical technology company with extensive expertise in biomaterials based medical devices for pre-hospital, intra-operative and post-operative clinical needs. Our focus is on devices for management of trauma, surgical and chronic wounds. Our flagship product, Axiostat, is a patented, clinically validated haemostat that stops moderate to severe bleeding instantly in surgeries and in pre-hospital trauma. Axiostat is USFDA 510(k) cleared and is also European CE approved. In Advanced Wound Care range, Axio has launched the next-generation MaxioCel wound dressing. MaxioCel is designed to heal patients suffering from acute and chronic wounds (diabetic foot ulcers, pressure ulcers, burns, bed sores, cavity wounds and surgical site infections) by effectively managing exudates, pain reduction and scar less healing.

Axolotl Biosciences provides turn-key reagents such as functional bioinks, 3D tissue models, and consulting services in the field of 3D bioprinting. Our goal is to improve human health through novel 3D printing technologies.

Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Itsunique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape.